Pharma Two B Ltd. Commences Phase 2b Study Of Fixed Dose Combination Therapy “P2B001” For Parkinson’s Disease
3/18/2014 9:25:42 AM
REHOVOT, Israel--(BUSINESS WIRE)--Pharma Two B announced today that it is now enrolling patients for a Phase IIb study of its combination product, P2B001, for the treatment of the early stages of Parkinson’s disease (PD). Pharma Two B is following the FDA’s 505(b)(2) registration pathway for P2B001.
Help employers find you! Check out all the jobs and post your resume.
comments powered by